Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly CEO Dave Ricks reported that since the launch of Medicare coverage for obesity drugs in July, 700,000 new seniors have begun GLP-1 treatments, with 70% opting for Lilly medications. The coverage allows eligible seniors to access weight loss drugs for a $50 monthly co-pay. Lilly's Zepbound and Foundayo are noted as leading choices among patients, with one-third of new oral GLP-1 patients using Foundayo. The increase in patients shows significant market expansion for obesity treatments, which potentially benefits Eli Lilly (LLY) significantly.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) Price Target Increased to $1,400, Analysts See 25% Upside
- AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
- Eli Lilly (LLY) Receives UK Approval for Orforglipron Weight Diabetes Drug
- Eli Lilly (LLY) Raises Price Target After Positive Quarter Results
- Lilly's Mounjaro and Zepbound Sales Surge Over Novo Nordisk
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
